TMC4

Across TCGA pan-cancer cohorts, TMC4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMC4 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMC4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TMC4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where TMC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.983	0.775	<.001	63	view →
LSCC	OS	Tertile	All	0.694	0.973	<.001	48	view →
PDAC	OS	Median	III,IV	0.503	0.975	.004	24	view →
LUAD	DFS	Quartile	All	0.644	0.912	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMC4–CCRCC (OS)

Open the CCRCC breakdown →